Distinct placental molecular processes associated with early-onset and late-onset preeclampsia

Zhonglu Ren,Yunfei Gao,Yue Gao,Guanmei Liang,Qian Chen,Sijia Jiang,Xiaoxue Yang,Cuixia Fan,Haizhen Wang,Jing Wang,Yi-Wu Shi,Chaoqun Xiao,Mei Zhong,Xinping Yang
DOI: https://doi.org/10.7150/thno.56141
IF: 11.6
2021-01-01
Theranostics
Abstract:<p><b>Background:</b> Patients with preeclampsia display a spectrum of onset time and severity of clinical presentation, yet the underlying molecular bases for the early-onset and late-onset clinical subtypes are not known. Although several transcriptome studies have been done on placentae from PE patients, only a small number of differentially expressed genes have been identified due to very small sample sizes and no distinguishing of clinical subtypes.</p><p><b>Methods:</b> We carried out RNA-seq on 65 high-quality placenta samples, including 33 from 30 patients and 32 from 30 control subjects, to search for dysregulated genes and the molecular network and pathways they are involved in.</p><p><b>Results:</b> We identified two functionally distinct sets of dysregulated genes in the two major subtypes: 2,977 differentially expressed genes in early-onset severe preeclampsia, which are enriched with metabolism-related pathways, notably transporter functions; and 375 differentially expressed genes in late-onset severe preeclampsia, which are enriched with immune-related pathways. We also identified some key transcription factors, which may drive the widespread gene dysregulation in both early-onset and late-onset patients.</p><p><b>Conclusion:</b> These results suggest that early-onset and late-onset severe preeclampsia have different molecular mechanisms, whereas the late-onset mild preeclampsia may have no placenta-specific causal factors. A few regulators may be the key drivers of the dysregulated molecular pathways.</p>
medicine, research & experimental
What problem does this paper attempt to address?